The ORIGIN Trial Investigators. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med, 2012; 367: 319–328.
2.
LaneW, BaileyTS, GeretyG, et al.Effect of insulin degludec vs insulin glargine U100 on hypoglycemia in patients with type 1 diabetes. The SWITCH 1 randomized clinical trial. JAMA, 2017; 318: 33–44.
3.
WyshamC, BhargavaA, ChaykinL, et al.Effect of insulin degludec vs insulin glargine U100 on hypoglycemia in patients with type 2 diabetes. The SWITCH 2 randomized clinical trial. JAMA, 2017; 318: 45–56.
4.
KumarA, FranekE, WiseJ, NiemeyerM, MersbachH, Simó. Efficacy and safety of once-daily insulin degludec/insulin aspart versus insulin glargine (U100) for 52 weeks in insulin-naïve patients with type 2 diabetes: a randomized controlled trail. PLoS one 2016 OCT, 19; 11: e0163350.
5.
HomePD, BergenstalRM, BolliGB, et al.New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 1 diabetes: a randomized, phase 3a, open-label clinical trial (EDITION 4). Diabetes Care, 2015; 38: 2217–2225.
6.
MatsuhisaM, KoyamaM, ChengX, et al.New insulin glargine 300 U/mL versus glargine 100 U/mL in Japanese adults with type 1 diabetes using basal and mealtime insulin: glucose control and hypoglycaemia in a randomized controlled trial (EDITION JP1). Diabetes Obes Metab, 2016; 18: 375–383.
7.
PerrinC, EwenM, BeranD. The role of biosimilar manufacturers in improving access to insulin globally. Lancet Diabetes Endocrinol, 2017.
8.
DowlatHA, KuhlmannMK, KhatamiH, Ampudia-BlascoFJ. Interchangeability among reference insulin analogues and their biosimilars: regulatory framework, study design and clinical implications. Diabetes Obes Metab, 2016; 18: 737–746.
9.
HeinemannL, FritzI, KhatamiH, EdelmanSV. Administration of biosimilar insulin analogs: role of devices. Diabetes Technol Ther, 2017; 19:79–84.
10.
MeneghiniLF, McNultyJN. Role of devices in insulin delivery. Diabetes Technol Ther, 2017; 19: 76–78.
11.
LinnebjergH, LamEC, ZhangX, SegerME, CoutantD, ChuaL, KapitzaC, HeiseT. Duration of action of two insulin glargine products, LY2963016 insulin glargine and Lantus insulin glargine, in subjects with type 1 diabetes mellitus. Diabetes Obes Metab, 2017; 19: 33–39.
12.
KapitzaC, NowotnyI, LehmannA, BergmannK, RotthaeuserB, NosekL, BeckerRHA. Similar pharmacokinetics and pharmacodynamics of rapid-acting insulin lispro products SAR342434 and US- and EU-approved Humalog in subjects with type 1 diabetes. Diabetes Obes Metab, 2017; 19: 622–627.
13.
KramerI, BluherM, KuhlmannMK, HeinemannL. [Practical aspects in the use of biosimilar insulins]. Dtsch Med Wochenschr, 2016; 141: 1565–1568.
14.
MonnigE, SchlootN, HohbergC, WiesnerT, HeinemannL. [Comparison of two insulin glargine formulations: biosimilar vs. reference product]. MMW Fortschr Med, 2016; 158 (Suppl 5): 19–27.
15.
DaviesM, DahlD, HeiseT, KiljanskiJ, MathieuC. Introduction of similar insulins in Europe. Diabet Med, 2017; 34: 1340–1353.
16.
KimAP, BindlerRJ. The future of biosimilar insulins. Diabetes Spectr, 2016; 29: 161–166.
17.
ByrdRA, OwensRA, BlackbourneJL, CoutantDE, FarmenMW, MichaelMD, MoyersJS, SchultzeAE, SievertMK, TripathiNK, VahleJL. Nonclinical pharmacology and toxicology of the first biosimilar insulin glargine drug product (BASAGLAR(R)/ABASAGLAR(R)) approved in the European Union. Regul Toxicol Pharmacol, 2017; 88: 56–65.
18.
ChapmanSR, FitzpatrickRW, AladulMI. Knowledge, attitude and practice of healthcare professionals towards infliximab and insulin glargine biosimilars: result of a UK web-based survey. BMJ Open, 7: e016730.
19.
FullertonB, SiebenhoferA, JeitlerK, HorvathK, SemlitschT, BergholdA, PlankJ, PieberTR, GerlachFM. Short-acting insulin analogues versus regular human insulin for adults with type 1 diabetes mellitus. Cochrane Database Syst Rev, 2016; 6: CD012161.
20.
CengizE, BodeB, Van NameM, TamborlaneWV. Moving toward the ideal insulin for insulin pumps. Expert Rev Med Devices, 2016; 13: 57–69.
21.
DanneT, NimriR, BattelinoT, BergenstalRM, CloseKL, DeVriesJH, GargS, HeinemannL, HirschI, AmielSA, BeckR, BosiE, BuckinghamB, CobelliC, DassauE, DoyleFJ, HellerS, HovorkaR, JiaW, JonesT, KordonouriO, KovatchevB, KowalskiA, LaffelL, MaahsD, MurphyHR, NørgaardK, ParkinCG, RenardE, SabooB, ScharfM, TamborlaneWV, WeinzimerSA, PhillipM. International Consensus on use of continuous glucose monitoring. Diabetes Care 2017 Diabetes Care, 2017; 40: 1631–1640.
